RenovoRx, Inc. Common Stock (RNXT) Stock
Key stats
- Market cap
- $58.87M
- Price / Earnings ratio
- -4.4x
- EPS (TTM)
- -$0.31
- Volume
- Loading
- 52-week high
- $2.59
- 52-week low
- $0.70
Source: third-party data provider, as of November 13, 2026
Compare with RNXT
Recent news

RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RNXT

RenovoRx Q2 Earnings Call Highlights
RenovoRx Q2 Earnings Call Highlights
RNXT

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RNXT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 44.11
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.06
- MACD histogram
- -0.00
- SMA 50
- $1.50
- Price below SMA 50
- EMA 50
- $1.34
- Price below EMA 50
- SMA 200
- $1.11
- Price above SMA 200
- EMA 200
- $1.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RNXT

RenovoRx Q2 Earnings Call Highlights
RenovoRx Q2 Earnings Call Highlights
RNXT

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RNXT
News tone: automated (AI) classification of the article's content, not a price prediction.
About RenovoRx, Inc. Common Stock
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Shaun R. Bagai | CEO, Secretary & Director | 1977 |
| Dr. Ramtin Agah M.D. | Founder, Executive Chairman & Chief Medical Officer | 1966 |
| Mr. Mark Voll | CFO & Principal Accounting Officer | 1955 |
| Mr. Ronald B. Kocak CPA, CGMA | VP of Finance & Controller | 1958 |
| Mr. Tom Kelly | Vice President of Quality & Operations | — |
| Mr. Phil Stocton | Vice President of Sales & Market Development | — |
| Ms. Leesa Gentry | Chief Clinical Officer | 1970 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.11
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.06
- MACD histogram
- -0.00
- SMA 50
- $1.50
- Price below SMA 50
- EMA 50
- $1.34
- Price below EMA 50
- SMA 200
- $1.11
- Price above SMA 200
- EMA 200
- $1.17
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $15.00
- Average
- $15.00
- High
- $15.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +15.6 | -26.1 | -14.2 | -3.2 |



